|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 74-76.
Prepublished online as a Blood First Edition Paper on September 7, 2004; DOI 10.1182/blood-2004-05-1711.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
David Saadoun,
Felipe Suarez,
François Lefrere,
Françoise Valensi,
Xavier Mariette,
Achille Aouba,
Caroline Besson,
Bruno Varet,
Xavier Troussard,
Patrice Cacoub, and
Oliver Hermine
From the Department of Hematology, Hôpital Necker, Paris, France; Department of Rheumatology, Hôpital de Kremlin-Bicêtre, Le Kremlin-Bicêtre, France; Department of Hematology, CHU Côte de Nacre, Caen, France; and Department of Internal Medicine, Hôpital Pitié-Salpétrière, Paris, France.
Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the regression of splenic lymphoma with villous lymphocytes (SLVL) in patients with HCV after antiviral treatment, demonstrating a direct role of HCV in lymphomagenesis. This study expands our previous results in 18 patients with chronic HCV and SLVL. Mixed cryoglobulinemia (MC) was present in all cases and was symptomatic in 13 (72%). All patients were treated with interferon alone or in association with ribavirin. Hematologic and virologic responses were correlated. Fourteen (78%) patients achieved a sustained complete hematologic response after clearance of HCV RNA. Two patients had a virologic partial response and achieved a complete hematologic response. Two virologic nonresponders achieved partial hematologic response. Regardless of the response, monoclonal immunoglobulin gene rearrangement persisted after treatment. This study underscores the role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B Terrier, D Sene, D Saadoun, P Ghillani-Dalbin, V Thibault, A Delluc, J-C Piette, and P Cacoub
Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders
Ann Rheum Dis,
January 1, 2009;
68(1):
89 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D S Viswanatha and A Dogan
Hepatitis C virus and lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1378 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Saadoun, J. Sellam, P. Ghillani-Dalbin, R. Crecel, J.-C. Piette, and P. Cacoub
Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.
Arch Intern Med,
October 23, 2006;
166(19):
2101 - 2108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Besson, F. Lefrere, F. Suarez, F. Reyes, and O. Hermine
In Reply
J. Clin. Oncol.,
July 20, 2006;
24(21):
3513 - 3514.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al.
Splenic marginal zone lymphoma: a prognostic model for clinical use
Blood,
June 15, 2006;
107(12):
4643 - 4649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bertoni and E. Zucca
State-of-the-Art Therapeutics: Marginal-Zone Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6415 - 6420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
